Arsanis, Inc., a clinical-stage biopharmaceutical company focused on applying monoclonal antibody immunotherapies to address serious infectious diseases, today announced that the company presented positive preclinical efficacy data in prevention and treatment models of lethal Staphylococcus aureus pneumonia for its investigational lead product candidate, ASN100, which is currently in a Phase 2 clinical trial for the prevention of S. aureus pneumonia in high-risk, mechanically ventilated patients. These data were described in two poster presentations at the 2017 ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, taking place in Boston from September 6 – 8. 

Axonics Modulation Technologies, Inc., developer of the first rechargeable Sacral Neuromodulation (r-SNM™) system for the treatment of urinary and bowel dysfunction, today announced the appointment of Karen L. Noblett, M.D., M.A.S., a urogynecologist and prolific clinical researcher, as Chief Medical Officer.

InDex Pharmaceuticals Holding AB (publ) today announced that the US Food and Drug Administration (FDA) has granted orphan-drug designation for the drug candidate cobitolimod for treatment of ulcerative colitis in pediatric patients.

Genkyotex (Euronext Paris & Brussels: FR00011790542 – GKTX), a biopharmaceutical company and the leader in NOX therapies, announced today that data in multiple preclinical models showed that GKT831, the Company’s NOX1 and NOX4 inhibitor, efficiently targeted cancer associated fibroblasts (CAFs) and delayed tumor growth. The results from this study were published in the Journal of the National Cancer Institute (https://doi.org/10.1093/jnci/djx121).